Neural Therapeutics Inc. NURL
CNSX
| 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 622.20K | 641.90K | 643.00K | 407.60K | 279.50K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 640.70K | 665.50K | 699.10K | 496.00K | 395.10K |
| Operating Income | -640.70K | -665.50K | -699.10K | -496.00K | -395.10K |
| Income Before Tax | -893.70K | -693.40K | -720.60K | -998.60K | -398.30K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -0.89 | -0.69 | -0.72 | -1.00 | -0.40 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -893.70K | -693.40K | -720.60K | -998.60K | -398.30K |
| EBIT | -640.70K | -665.50K | -699.10K | -496.00K | -395.10K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | 0.00 | 0.00 |
| EPS Diluted | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 482.97M | 392.10M | 300.48M | 277.56M | 264.06M |
| Average Diluted Shares Outstanding | 482.97M | 392.10M | 300.48M | 277.56M | 264.06M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |